Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, open-label, randomised, phase III study of 2 cycles of oral vinorelbine in combination with cisplatin concurrently with radiotherapy randomised to either two more cycles of consolidation therapy with oral vinorelbine and cisplatin plus Best Supportive Care (BSC) or BSC alone in patients with unresectable locally advanced non small cell lung cancer (NSCLC).

The primary objective is to compare progression-free survival in both arms, the secondary is to evaluate the response rate, overall survival in both arms, to evaluate the safety profile in both arms and to assess quality of life by the LCSS questionnaire.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pierre Fabre Medicament
• Collaborator: Pierre Fabre Pharma GmbH
• Treatments: Cisplatin; Vinblastine; Vinorelbine

Criteria

Main Inclusion Criteria:

• Presence of at least one measurable lesion (RECIST criteria)

• Patients with a Karnofsky Performance Status = or > 80%

• Adequate pulmonary function, bone marrow, hepatic and renal functions

Main Exclusion Criteria:

• Patients with NSCLC stage IV, with NSCLC stages I, II, IIIA (except N2), with NSCLC stage IIIB with tumour extent or pleural effusion

• Symptomatic neuropathy > Grade 1

• Hearing impairment = or > Grade 2

• Concomitant/uncontrolled medical disorder

• Pregnant women